Porpora trombotica trombocitopenica, dal New England conferme di efficacia per Caplacizumab

https://www.pharmastar.it/news/oncoemato/porpora-trombotica-trombocitopenica-dal-new-england-conferme-di-efficacia-per-caplacizumab-28528

[ENG] QOL-ONE III ANNUAL CONFERENCE SINDROMI MIELODISPLASTICHE E COMPLICANZE 29 Settembre 2018

Usern Congress and Prize Festival – Reggio Calabria (Italy) November 10th 2018 -Mediterranea University – Reggio Calabria

Qol-One investigator Meeting on Rev2MDS Trial @ASH – Dec. 11 2017

By invitation only. To discus Rev2MDS (Efficacy of eltrombopag plus Lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study).

Collaboration Room Number 26 in Hall B1.

Registration

or register

Register USERN

Welcome to the registration form

Tuition and fees are different for participants from developing countries and from other countries. Developing countries are those recognized as such by the International Monetary Fund.
Tuition and fees are also different for Junior participants (born after December 31th 1977) and Senior participants (born before December 31th 1977).
Send us your short CV. Please mention Institutions where you trained, including your mentors and their e-mail addresses.
Costs For Developing country:
  • Juniors (born after December 31th 1977) € 250,00
  • Seniors € 350,00
Other country:
  • Juniors (born after December 31th 1977) € 350,00
  • Seniors € 450,00